IP and publication reasons basically. We want to share with you all an overview of the important aspects of the results while still allowing the data to be protected and published in quality peer-reviewed scientific journals.
This balance between IP protection and sharing is a difficult one and in my opinion it is important to achieve a balance. Going too far in either direction destroys shareholder value.
Ann: Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells, page-84
-
- There are more pages in this discussion • 135 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.70 |
Change
0.090(5.59%) |
Mkt cap ! $289.5M | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.76 | $1.59 | $142.7K | 84.97K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 17175 | $1.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.77 | 6060 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |